本靶向药物输送系统可以提高抗肿瘤药物疗效、降低毒副作用。已于2018年8月开始在澳大利亚进行针对转移性胰腺癌的一期临床试验。

       ●特异靶向实体瘤新生血管

       ●引导药物穿透血管壁进入实体瘤内部（至少3mm）

       ●物理混合即可生效：无需化学修饰或包装药物载荷

       This tumor penetrating peptide technology The targeted drug delivery system can improve the efficacy of anti-tumor drugs and reduce toxicity and other side decrease toxic and side effect.  Phase I clinical trial was initiated in August 2018 in Australia for patients with metastatic pancreatic ductal adenocarcinoma.
       ●Target tumor angiogenesis with high specificity
       ●Active transport drugs through blood vessels into solid tumor (deeper than 3mm)
       ●Bystander effect: no covalent modification or encapsulation needed for payloads